Innate immune memory: Implications for host responses to damage-associated molecular patterns

European Journal of Immunology

Volumn 46, Issue 4, 2016, Pages 817-828

  Crisan, Tania O ^a,b   Netea, Mihai G ^a   Joosten, Leo A B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Damage associated molecular patterns Epigenetics Innate immune memory Trained immunity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH DENSITY LIPOPROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN; URATE; URIC ACID; CYTOKINE; PATTERN RECOGNITION RECEPTOR;

AUTOINFLAMMATORY DISEASE; CYTOKINE PRODUCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFLAMMATION; INNATE IMMUNITY; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TISSUE INJURY; BIOSYNTHESIS; IMMUNOLOGY; SIGNAL TRANSDUCTION;

CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INFLAMMATION; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 84962890393     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545497     Document Type: Review

References (113)

1. Akira, S., Uematsu, S. and Takeuchi, O., Pathogen recognition and innate immunity. Cell 2006. 124: 783-801.
2. Netea, M. G., Quintin, J. and van der Meer, J. W., Trained immunity: a memory for innate host defense. Cell Host Microbe 2011. 9: 355-361.
3. Netea, M. G., Latz, E., Mills, K. H. and O'Neill, L. A., Innate immune memory: a paradigm shift in understanding host defense. Nat. Immunol. 2015. 16: 675-679.
4. Benn, C. S., Netea, M. G., Selin, L. K. and Aaby, P., A small jab-a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013. 34: 431-439.
5. Levy, O. and Netea, M. G., Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines. Pediatr. Res. 2014. 75: 184-188.
6. Matzinger, P., The danger model: a renewed sense of self. Science 2002. 296: 301-305.
7. Land, W. G., The role of damage-associated molecular patterns in human diseases: part I-promoting inflammation and immunity. Sultan Qaboos Univ. Med. J. 2015. 15: e9-e21.
8. Quintin, J., Saeed, S., Martens, J. H., Giamarellos-Bourboulis, E. J., Ifrim, D. C., Logie, C., Jacobs, L. et al., Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012. 12: 223-232.
9. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A., Ifrim, D. C., Saeed, S., Jacobs, C. et al., Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 2012. 109: 17537-17542.
10. Tribouley, J., Tribouley-Duret, J. and Appriou, M., [Effect of Bacillus Callmette Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni]. C R Seances Soc. Biol. Fil. 1978. 172: 902-904.
11. van 't Wout, J. W., Poell, R. and van Furth, R., The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand. J. Immunol. 1992. 36: 713-719.
12. Bistoni, F., Vecchiarelli, A., Cenci, E., Puccetti, P., Marconi, P. and Cassone, A., Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun. 1986. 51: 668-674.
13. Bistoni, F., Verducci, G., Perito, S., Vecchiarelli, A., Puccetti, P., Marconi, P. and Cassone, A., Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J. Med. Vet. Mycol. 1988. 26: 285-299.
14. Vecchiarelli, A., Cenci, E., Puliti, M., Blasi, E., Puccetti, P., Cassone, A. and Bistoni, F., Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol. 1989. 124: 334-344.
15. Chen, F., Wu, W., Millman, A., Craft, J. F., Chen, E., Patel, N., Boucher, J. L. et al., Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. Nat. Immunol. 2014. 15: 938-946.
16. Aaby, P., Roth, A., Ravn, H., Napirna, B. M., Rodrigues, A., Lisse, I. M., Stensballe, L. et al., Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect Dis. 2011. 204: 245-252.
17. Biering-Sorensen, S., Aaby, P., Napirna, B. M., Roth, A., Ravn, H., Rodrigues, A., Whittle, H. and Benn, C. S., Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr. Infect Dis. J. 2012. 31: 306-308.
18. Shann, F., The non-specific effects of vaccines. Arch. Dis. Child 2010. 95: 662-667.
19. Barton, E. S., White, D. W., Cathelyn, J. S., Brett-McClellan, K. A., Engle, M., Diamond, M. S., Miller, V. L. and Virgin, H. W. t., Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007. 447: 326-329.
20. Hong, M., Sandalova, E., Low, D., Gehring, A. J., Fieni, S., Amadei, B., Urbani, S. et al., Trained immunity in newborn infants of HBV-infected mothers. Nat Commun 2015. 6: 6588.
21. Saeed, S., Quintin, J., Kerstens, H. H., Rao, N. A., Aghajanirefah, A., Matarese, F., Cheng, S. C. et al., Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014. 345: 1251086.
22. Fan, H. and Cook, J. A., Molecular mechanisms of endotoxin tolerance. J. Endotoxin. Res. 2004. 10: 71-84.
23. Ifrim, D. C., Quintin, J., Joosten, L. A. B., Jacobs, C., Jansen, T., Jacobs, L., Gow, N. A. R. et al., Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin. Vaccine Immunol. 2014. 21: 534-545.
24. Chen, K., Geng, S., Yuan, R., Diao, N., Upchurch, Z. and Li, L., Super-low dose endotoxin pre-conditioning exacerbates sepsis mortality. EBioMedicine 2015. 2: 324-333.
25. Morris, M. C., Gilliam, E. A., Button, J. and Li, L., Dynamic modulation of innate immune response by varying dosages of lipopolysaccharide (LPS) in human monocytic cells. J. Biol. Chem. 2014. 289: 21584-21590.
26. Locati, M., Mantovani, A. and Sica, A., Macrophage activation and polarization as an adaptive component of innate immunity. Adv. Immunol. 2013. 120: 163-184.
27. Gordon, S. and Taylor, P. R., Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005. 5: 953-964.
28. Mosser, D. M. and Edwards, J. P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008. 8: 958-969.
29. Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., Curina, A., Prosperini, E., Ghisletti, S. and Natoli, G., Latent enhancers activated by stimulation in differentiated cells. Cell 2013. 152: 157-171.
30. Bierne, H., Hamon, M. and Cossart, P., Epigenetics and bacterial infections. Cold Spring Harb. Perspect. Med. 2012. 2: a010272.
31. Cheng, S. C., Quintin, J., Cramer, R. A., Shepardson, K. M., Saeed, S., Kumar, V., Giamarellos-Bourboulis, E. J. et al., mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014. 345: 1250684.
32. Warburg, O., Wind, F. and Negelein, E., The metabolism of tumors in the body. J. Gen. Physiol. 1927. 8: 519-530.
33. Warburg, O., On the origin of cancer cells. Science 1956. 123: 309-314.
34. Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C. et al., Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013. 496: 238-242.
35. Berrien-Elliott, M. M., Wagner, J. A. and Fehniger, T. A., Human cytokine-induced memory-like natural killer cells. J. Innate Immun. 2015. 7: 563-571.
36. Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A. and Yokoyama, W. M., Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA 2009. 106: 1915-1919.
37. Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A. and Fehniger, T. A., Cytokine activation induces human memory-like NK cells. Blood 2012. 120: 4751-4760.
38. Sun, J. C., Beilke, J. N. and Lanier, L. L., Adaptive immune features of natural killer cells. Nature 2009. 457: 557-561.
39. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A., Jacobs, C., Xavier, R. J., van der Meer, J. W., van Crevel, R. and Netea, M. G., BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin. Immunol. 2014. 155: 213-219.
40. Askenase, M. H., Han, S. J., Byrd, A. L., Morais da Fonseca, D., Bouladoux, N., Wilhelm, C., Konkel, J. E. et al., Bone-marrow-resident NK cells prime monocytes for regulatory function during Infection. Immunity 2015. 42: 1130-1142.
41. Sonnenberg, G. F. and Artis, D., Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat. Med. 2015. 21: 698-708.
42. Minassian, A. M., Satti, I., Poulton, I. D., Meyer, J., Hill, A. V. and McShane, H., A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J. Infect Dis. 2012. 205: 1035-1042.
43. Burgess, S. L., Buonomo, E., Carey, M., Cowardin, C., Naylor, C., Noor, Z., Wills-Karp, M. and Petri, W. A., Jr., Bone marrow dendritic cells from mice with an altered microbiota provide interleukin 17A-dependent protection against Entamoeba histolytica colitis. MBio 2014. 5: e01817.
44. Yanez, A., Hassanzadeh-Kiabi, N., Ng, M. Y., Megias, J., Subramanian, A., Liu, G. Y., Underhill, D. M. et al., Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce. Eur. J. Immunol. 2013. 43: 2114-2125.
45. Bekkering, S., Joosten, L. A., van der Meer, J. W., Netea, M. G. and Riksen, N. P., Trained innate immunity and atherosclerosis. Curr. Opin. Lipidol. 2013. 24: 487-492.
46. Burnet, F. M., The Clonal Selection Theory of Acquired Immunity. Vanderbilt University Press, Nashville, 1959.
47. Medzhitov, R. and Janeway, C. A., Jr., Decoding the patterns of self and nonself by the innate immune system. Science 2002. 296: 298-300.
48. Matzinger, P., Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994. 12: 991-1045.
49. Land, W., Schneeberger, H., Schleibner, S., Illner, W. D., Abendroth, D., Rutili, G., Arfors, K. E. and Messmer, K., The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994. 57: 211-217.
50. Pradeu, T. and Cooper, E. L., The danger theory: 20 years later. Front Immunol. 2012. 3: 287.
51. Matzinger, P., Friendly and dangerous signals: is the tissue in control? Nat. Immunol. 2007. 8: 11-13.
52. Huang, J., Xie, Y., Sun, X., Zeh, H. J., 3rd, Kang, R., Lotze, M. T. and Tang, D., DAMPs, ageing, and cancer: the 'DAMP Hypothesis'. Ageing Res. Rev. 2014. 24: 3-16.
53. Heil, M. and Land, W. G., Danger signals-damaged-self recognition across the tree of life. Front Plant Sci. 2014. 5: 578.
54. Chen, G. Y. and Nunez, G., Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010. 10: 826-837.
55. Feldman, N., Rotter-Maskowitz, A. and Okun, E., DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res. Rev. 2015. 24: 29-39.
56. Land, W. G., The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ. Med. J. 2015. 15: e157-e170.
57. Scaffidi, P., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002. 418: 191-195.
58. Bresnick, A. R., Weber, D. J. and Zimmer, D. B., S100 proteins in cancer. Nat. Rev. Cancer 2015. 15: 96-109.
59. Pruenster, M., Kurz, A. R., Chung, K. J., Cao-Ehlker, X., Bieber, S., Nussbaum, C. F., Bierschenk, S. et al., Extracellular MRP8/14 is a regulator of beta2 integrin-dependent neutrophil slow rolling and adhesion. Nat. Commun. 2015. 6: 6915.
60. Holzinger, D., Nippe, N., Vogl, T., Marketon, K., Mysore, V., Weinhage, T., Dalbeth, N. et al., Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 2014. 66: 1327-1339.
61. Kim, B., Lee, Y., Kim, E., Kwak, A., Ryoo, S., Bae, S. H., Azam, T. et al., The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol. 2013. 4: 391.
62. Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R. et al., IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 2011. 187: 4835-4843.
63. Toki, Y., Takenouchi, T., Harada, H., Tanuma, S., Kitani, H., Kojima, S. and Tsukimoto, M., Extracellular ATP induces P2×7 receptor activation in mouse Kupffer cells, leading to release of IL-1beta, HMGB1, and PGE2, decreased MHC class I expression and necrotic cell death. Biochem. Biophys. Res. Commun. 2015. 458: 771-776.
64. Ghaemi-Oskouie, F. and Shi, Y., The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr. Rheumatol. Rep. 2011. 13: 160-166.
65. Hansson, G. K. and Hermansson, A., The immune system in atherosclerosis. Nat. Immunol. 2011. 12: 204-212.
66. Joosten, L. A., Netea, M. G., Mylona, E., Koenders, M. I., Malireddi, R. K., Oosting, M., Stienstra, R. et al., Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010. 62: 3237-3248.
67. Rajasekar, P., O'Neill, C. L., Eeles, L., Stitt, A. W. and Medina, R. J., Epigenetic changes in endothelial progenitors as a possible cellular basis for glycemic memory in diabetic vascular complications. J. Diabetes Res. 2015. 2015: 436879.
68. Jay, A. G., Chen, A. N., Paz, M. A., Hung, J. P. and Hamilton, J. A., CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding. J. Biol. Chem. 2015. 290: 4590-4603.
69. Sirisinha, S., Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac. J. Allergy Immunol. 2011. 29: 1-14.
70. Linton, M. R. F., Yancey, P. G., Davies, S. S., Vickers, K. C., Jerome, W. G. J. and Linton, E. F., The role of lipids and lipoproteins in atherosclerosis. In De Groot, L. J., Beck-Peccoz, P., Chrousos, G., Dungan, K., Grossman, A., Hershman, J. M., Koch, C., McLachlan, R., New, M., Rebar, R., Singer, F., Vinik, A. and Weickert, M. O. (Eds.), Endotext, South Dartmouth, MA, 2000.
71. Lamb, D. J., Eales, L. J. and Ferns, G. A., Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 1999. 143: 105-113.
72. Bekkering, S., Quintin, J., Joosten, L. A., van der Meer, J. W., Netea, M. G. and Riksen, N. P., Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler. Thromb. Vasc. Biol. 2014. 34: 1731-1738.
73. Wierda, R. J., Geutskens, S. B., Jukema, J. W., Quax, P. H. and van den Elsen, P. J., Epigenetics in atherosclerosis and inflammation. J. Cell Mol. Med. 2010. 14: 1225-1240.
74. Lund, G. and Zaina, S., Atherosclerosis: an epigenetic balancing act that goes wrong. Curr. Atheroscler. Rep. 2011. 13: 208-214.
75. Mitra, S., Khaidakov, M., Lu, J., Ayyadevara, S., Szwedo, J., Wang, X. W., Chen, C., Khaidakov, S., Kasula, S. R., Stone, A., Pogribny, I. and Mehta, J. L., Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Am. J. Physiol. Heart Circ. Physiol. 2011. 301: H506-H513.
76. van Kampen, E., Jaminon, A., van Berkel, T. J. and Van Eck, M., Diet-induced (epigenetic) changes in bone marrow augment atherosclerosis. J. Leukoc. Biol. 2014. 96: 833-841.
77. De Nardo, D., Labzin, L. I., Kono, H., Seki, R., Schmidt, S. V., Beyer, M., Xu, D. et al., High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 2014. 15: 152-160.
78. Athyros, V. G. and Mikhailidis, D. P., Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors. J. Diabetes Compl. 2014. 28: 122-123.
79. Eisenbacher, J. L., Schrezenmeier, H., Jahrsdorfer, B., Kaltenmeier, C., Rojewski, M. T., Yildiz, T., Beyer, T. et al., S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. J. Immunol. 2014. 192: 6102-6110.
80. Shi, Y., Evans, J. E. and Rock, K. L., Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003. 425: 516-521.
81. Kono, H., Chen, C. J., Ontiveros, F. and Rock, K. L., Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 2010. 120: 1939-1949.
82. Martinon, F., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006. 440: 237-241.
83. Misawa, T., Takahama, M., Kozaki, T., Lee, H., Zou, J., Saitoh, T. and Akira, S., Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 2013. 14: 454-460.
84. Giamarellos-Bourboulis, E. J., Mouktaroudi, M., Bodar, E., van der Ven, J., Kullberg, B. J., Netea, M. G. and van der Meer, J. W., Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann. Rheum. Dis. 2009. 68: 273-278.
85. Mylona, E. E., Mouktaroudi, M., Crisan, T. O., Makri, S., Pistiki, A., Georgitsi, M., Savva, A. et al., Enhanced interleukin-1beta production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res. Ther. 2012. 14: R158.
86. An, L. L., Mehta, P., Xu, L., Turman, S., Reimer, T., Naiman, B., Connor, J., Sanjuan, M., Kolbeck, R. and Fung, M., Complement C5a potentiates uric acid crystal-induced IL-1beta production. Eur. J. Immunol. 2014. 44: 3669-3679.
87. Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A., Opitz, B., van der Meer, J. H., van de Veerdonk, F. L. et al., Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009. 113: 2324-2335.
88. Wang, Y., Viollet, B., Terkeltaub, R. and Liu-Bryan, R., AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann. Rheum. Dis. 2014. 75: 286-294.
89. Mylona, E. E., Mouktaroudi, M., Crisan, T. O., Makri, S., Pistiki, A., Georgitsi, M., Savva, A. et al., Enhanced interleukin-1b production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res. Ther. 2012. 14: R158.
90. Jansen, T. L., Berendsen, D., Crisan, T. O., Cleophas, M. C., Janssen, M. C. and Joosten, L. A., New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome. Clin. Rheumatol. 2014. 33: 1341-1346.
91. Crisan, T. O., Cleophas, M. C., Oosting, M., Lemmers, H., Toenhake-Dijkstra, H., Netea, M. G., Jansen, T. L. and Joosten, L. A., Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. 2015. 75: 755-762.
92. Lu, W., Xu, Y., Shao, X., Gao, F., Li, Y., Hu, J., Zuo, Z., Shao, X., Zhou, L., Zhao, Y. and Cen, X., Uric acid produces an inflammatory response through activation of NF-kappaB in the hypothalamus: implications for the pathogenesis of metabolic disorders. Sci. Rep. 2015. 5: 12144.
93. Roy, S., Sala, R., Cagliero, E. and Lorenzi, M., Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc. Natl. Acad. Sci. USA 1990. 87: 404-408.
94. El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E. and Brownlee, M., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 2008. 205: 2409-2417.
95. Lachmandas, E., Vrieling, F., Wilson, L. G., Joosten, S. A., Netea, M. G., Ottenhoff, T. H. and van Crevel, R., The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis. PLoS One 2015. 10: e0117941.
96. Togliatto, G., Dentelli, P. and Brizzi, M. F., Skewed epigenetics: an alternative therapeutic option for diabetes complications. J. Diabetes Res. 2015. 2015: 373708.
97. Jin, X., Yao, T., Zhou, Z., Zhu, J., Zhang, S., Hu, W. and Shen, C., Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-kappaB pathway. Biomed. Res. Int. 2015. 2015: 732450.
98. Andersson, U., Erlandsson-Harris, H., Yang, H. and Tracey, K. J., HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 2002. 72: 1084-1091.
99. Stros, M., HMGB proteins: interactions with DNA and chromatin. Biochim. Biophys. Acta 2010. 1799: 101-113.
100. Lee, S. A., Kwak, M. S., Kim, S. and Shin, J. S., The role of high mobility group box 1 in innate immunity. Yonsei Med. J. 2014. 55: 1165-1176.
101. Harris, H. E., Andersson, U. and Pisetsky, D. S., HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 2012. 8: 195-202.
102. Andersson, U. and Tracey, K. J., HMGB1 in sepsis. Scand. J. Infect Dis. 2003. 35: 577-584.
103. Huang, W., Tang, Y. and Li, L., HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010. 51: 119-126.
104. Park, S. Y., Lee, S. W., Kim, H. Y., Lee, W. S., Hong, K. W. and Kim, C. D., HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1alpha activation. Eur. J. Immunol. 2015. 45: 1216-1227.
105. Cai, J., Wen, J., Bauer, E., Zhong, H., Yuan, H. and Chen, A., The role HMGB1 in cardiovascular biology: danger signals. Antioxid. Redox Signal. 2015. 23: 1351-1369.
106. Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R. and Tsung, A., HMGB1: endogenous danger signaling. Mol. Med. 2008. 14: 476-484.
107. Gong, W., Zheng, Y., Chao, F., Li, Y., Xu, Z., Huang, G., Gao, X., Li, S. and He, F., The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail. J. Biomed. Biotechnol. 2010. 2010: 915234.
108. Valdes-Ferrer, S. I., Rosas-Ballina, M., Olofsson, P. S., Lu, B., Dancho, M. E., Li, J., Yang, H. et al., High-mobility group box 1 mediates persistent splenocyte priming in sepsis survivors: evidence from a murine model. Shock 2013. 40: 492-495.
109. Izuishi, K., Tsung, A., Jeyabalan, G., Critchlow, N. D., Li, J., Tracey, K. J., Demarco, R. A. et al., Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J. Immunol. 2006. 176: 7154-7158.
110. Morris, M. C., Gilliam, E. A. and Li, L., Innate immune programing by endotoxin and its pathological consequences. Front Immunol. 2014. 5: 680.
111. Blok, B. A., Arts, R. J., van Crevel, R., Benn, C. S. and Netea, M. G., Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J. Leukoc. Biol. 2015. 98: 347-356.
112. Redelman-Sidi, G., Glickman, M. S. and Bochner, B. H., The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat. Rev. Urol. 2014. 11: 153-162.
113. Buffen, K., Oosting, M., Quintin, J., Ng, A., Kleinnijenhuis, J., Kumar, V., van de Vosse, E. et al., Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014. 10: e1004485.